Vanda Pharmaceuticals Inc. (VNDA): Total Liabilities
$161.76M
As of 2025-12-31
$192.28M
As of 2026-06-30
+14.8%
3-year compound annual growth
+15.1%
5-year compound annual growth
+7.3%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $161.76M | +37.5% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $117.66M | +13.6% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $103.53M | -3.3% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $107.05M | +20.5% | 2024-02-08, Balance as of period end |
| 2021-12-31 | $88.86M | +10.8% | 2023-02-09, Balance as of period end |
| 2020-12-31 | $80.19M | +10.1% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $72.80M | +28.4% | 2021-02-11, Balance as of period end |
| 2018-12-31 | $56.71M | -23.4% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $74.04M | -6.3% | 2019-02-19, Balance as of period end |
| 2016-12-31 | $79.04M | -1.2% | 2018-02-15, Balance as of period end |
| 2015-12-31 | $80.02M | +635.0% | 2017-02-17, Balance as of period end |
| 2014-12-31 | $10.89M | -89.0% | 2016-02-12, Balance as of period end |
| 2013-12-31 | $99.22M | -21.0% | 2015-03-13, Balance as of period end |
| 2012-12-31 | $125.54M | -15.8% | 2014-02-25, Balance as of period end |
| 2011-12-31 | $149.14M | -15.0% | 2013-02-26, Balance as of period end |
| 2010-12-31 | $175.37M | n/a | 2012-03-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $161.76M | +37.5% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $211.49M | +6.2% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $86.39M | +33.0% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $85.96M | -29.1% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $343.95M | +27.5% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $65.98M | +55.1% |
Compare VNDA, AMRN, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗